PriceTargets.com logo

Calithera Biosciences - CALA Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$0.03 As of 04/18/2024 01:00 AM ET
▼ -0.015 (-37.45%)

This chart shows the closing price for CALA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Calithera Biosciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CALA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CALA

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Calithera Biosciences in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $0.03.

This chart shows the closing price for CALA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Calithera Biosciences. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/24/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/22/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/20/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/19/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/15/2022LADENBURG THALM/SH SHDowngradeBuy ➝ NeutralLow
11/15/2022SVB LeerinkDowngradeOutperform ➝ Market PerformLow
8/29/2022HC WainwrightUpgradeNeutral ➝ Buy$8.00Low
8/16/2022SVB LeerinkBoost TargetOutperform$18.00Low
5/11/2022LADENBURG THALM/SH SHLower Target$60.00 ➝ $30.00High
4/4/2022SVB LeerinkLower TargetOutperform$60.00 ➝ $40.00Medium
1/31/2022LADENBURG THALM/SH SHInitiated CoverageBuy$80.00High
1/20/2022SVB LeerinkUpgradeMarket Perform ➝ Outperform$60.00High
11/8/2021HC WainwrightDowngradeBuy ➝ NeutralMedium
11/5/2021William BlairDowngradeOutperform ➝ Market PerformHigh
8/9/2021HC WainwrightReiterated RatingBuy$80.00Low
5/10/2021HC WainwrightReiterated RatingBuy$80.00High
1/5/2021Smith Barney CitigroupLower Target$200.00 ➝ $100.00N/A
1/5/2021HC WainwrightLower TargetBuy$190.00 ➝ $80.00N/A
1/5/2021SVB LeerinkDowngradeOutperform ➝ Market Perform$140.00 ➝ $40.00N/A
8/11/2020SVB LeerinkLower TargetOutperform$180.00 ➝ $140.00High
6/2/2020William BlairReiterated RatingBuyMedium
5/11/2020CitigroupBoost TargetBuy$140.00 ➝ $200.00High
5/8/2020HC WainwrightReiterated RatingBuy$140.00 ➝ $190.00High
3/27/2020CitigroupLower TargetBuy$160.00 ➝ $140.00High
3/27/2020Jefferies Financial GroupInitiated CoverageBuy$120.00High
3/11/2020SVB LeerinkReiterated RatingOutperformHigh
11/27/2019HC WainwrightInitiated CoverageBuy$140.00High
11/19/2019HC WainwrightInitiated CoverageBuy$140.00High
8/9/2019CitigroupSet TargetHold$160.00Medium
6/21/2019William BlairReiterated RatingBuyLow
5/30/2019CitigroupReiterated RatingBuy$200.00Medium
(Data available from 4/19/2019 forward)

News Sentiment Rating

0.00 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/20/2024
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/19/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/20/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/19/2024

Current Sentiment

  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

  • No very positive mentions tracked during this time.
Calithera Biosciences logo
Calithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $0.03
Low: $0.03
High: $0.03

50 Day Range

MA: $0.02
Low: $0.02
High: $0.05

52 Week Range

Now: $0.03
Low: $0.01
High: $0.50

Volume

1,075 shs

Average Volume

857 shs

Market Capitalization

$121.99 thousand

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Calithera Biosciences?

The following sell-side analysts have issued reports on Calithera Biosciences in the last year: StockNews.com.
View the latest analyst ratings for CALA.

What is the current price target for Calithera Biosciences?

0 Wall Street analysts have set twelve-month price targets for Calithera Biosciences in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Calithera Biosciences in the next year.
View the latest price targets for CALA.

What is the current consensus analyst rating for Calithera Biosciences?

Calithera Biosciences currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for CALA.

What other companies compete with Calithera Biosciences?

Other companies that are similar to Calithera Biosciences include Athersys, Aptevo Therapeutics, Ampio Pharmaceuticals, Scopus BioPharma and Allarity Therapeutics. Learn More about companies similar to Calithera Biosciences.

How do I contact Calithera Biosciences' investor relations team?

Calithera Biosciences' physical mailing address is 343 OYSTER POINT BLVD. SUITE 200, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company's listed phone number is (650) 870-1000 and its investor relations email address is [email protected]. The official website for Calithera Biosciences is www.calithera.com. Learn More about contacing Calithera Biosciences investor relations.